Colorectal Cancer Clinical Trials Pipeline Analysis

New York, USA, Oct. 26, 2022 (GLOBE NEWSWIRE) — Colorectal Cancer Clinical Trials Pipeline Analysis Featuring 125+ Key Companies by DelveInsight

Colorectal Cancer Pipeline constitutes 125+ key companies continuously working towards developing 150+ Colorectal Cancer treatment therapies, analyzes DelveInsight

DelveInsight’s ‘Colorectal Cancer Pipeline Insight – 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline colorectal cancer therapies in various stages of clinical development, major pharmaceutical players working to advance the pipeline space and future growth potential of the colorectal cancer pipeline domain.

Key Takeaways from the Colorectal Cancer Pipeline Report

• DelveInsight’s colorectal cancer pipeline analysis depicts a robust space with 125+ active players working to develop 150+ pipeline therapies. 
• Some of the key pharmaceutical players working to develop potential colorectal cancer drug candidates to improve the colorectal cancer treatment landscape include Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics,  Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell,…